Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)

  • STATUS
    Recruiting
  • End date
    May 22, 2023
  • participants needed
    3056
  • sponsor
    Yonsei University
Updated on 22 January 2021
thrombosis
aspirin
sirolimus
ticagrelor
antiplatelet therapy
dapt

Summary

To compare the clinical outcomes of dual antiplatelet therapy with aspirin and ticagrelor vs. ticagrelor monotherapy at 3 months after PCI in patients with acute coronary syndrome.

Details
Condition Acute Coronary Syndrome, Ischemic Heart Disease, Cardiac Ischemia, Myocardial Ischemia, Cardiac Ischemia, Myocardial Ischemia, acute coronary syndromes
Treatment Ticagrelor monotherapy, Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)
Clinical Study IdentifierNCT02494895
SponsorYonsei University
Last Modified on22 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients 19 years old
Patients who received new generation sirolimus-eluting (Osiro) stent implantation for treating ACS
Patients without significant clinical events such as MI, stent thrombosis or revascularization until 3 months after PCI
Provision of informed consent

Exclusion Criteria

Age > 80 years
Increased risk of bleeding, anemia, thrombocytopenia
A need for oral anticoagulation therapy
Pregnant women or women with potential childbearing
Life expectancy < 1 year
Patients who treated with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir, or atazanavir)
Patients who had history of intracranial hemorrhage
Moderate to severe hepatic dysfunction
Increased risk of bradycardia-related symptom (Guidance and reference)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note